Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

NCT04489433 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Dabrafenib and Trametinib
DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

Novartis Pharmaceuticals